Skip to content

Eleusis Announces Published Research on Potential of Serotonin 2A Receptor Agonists to Treat Inflammation

— Study Published in Life Sciences Further Demonstrates Serotonin 2A Receptor Agonists Anti-Inflammatory Profile

London and New York - Oct. 15, 2019

Eleusis, a clinical stage life science company established to develop the therapeutic potential of serotonin 2A receptor (5-HT2A) agonists, also known as psychedelics, today announced new research published in Elsevier’s Life Sciences that demonstrates the anti-inflammatory properties of 5-HT2A agonists in a translational model of chronic asthma, a disease characterized by chronic allergic inflammatory response.

The publication, titled “5-HT2 Receptor Activation Alleviates Airway Inflammation and Structural Remodeling in a Chronic Mouse Asthma Model” shows the anti-inflammatory properties of 5-HT2A receptor agonists in a new mouse model of chronic asthma. The study highlights the capacity of 5-HT2A agonists to reverse airways hyperresponsiveness, a hallmark symptom of chronic asthma, in addition to reducing associated pulmonary inflammation and mucus overproduction. The study also reveals the capability of 5-HT2A agonists to reverse airway structural remodeling.

These data show that 5-HT2A agonists are efficacious to treat and rescue pre-existing inflammation, in addition to prevention of inflammation, and that their therapeutic effects may extend beyond inflammation. Notably, in the mouse model of chronic asthma, the study observed a 70% reduction in asthma-induced collagen deposition, which is associated with pulmonary fibrosis. Reduced asthma-induced collagen deposition is not observed in conjunction with systemic immunosuppression, further supporting the potential of 5-HT2A agonists as steroid-sparing alternatives for the treatment of chronic inflammatory disease.

“Our research with serotonin 5-HT2A receptor agonists suggest that they may represent a new strategy to treat ongoing and chronic inflammatory disease, and I am encouraged by these data that further our understanding of their therapeutic potential in a translational model of asthma,” said Charles Nichols Ph.D., the lead author of the study and Professor of Pharmacology at the Department of Pharmacology and Experimental Therapeutics at the Louisiana State University Health Sciences Center in New Orleans.

“These exciting new findings, in combination with the recently published results of our sponsored research in Scientific Reports, which revealed the anti-inflammatory properties of 5-HT2A agonists in cardiovascular disease, further validate the transformative potential of our proprietary 5-HT2A agonist pipeline to address urgent unmet needs across a broad spectrum of chronic inflammatory disease.” said Shlomi Raz, Chairman and Founder of Eleusis. “We look forward to advancing our lead candidate ELE-02 into clinical trials, and the further development of 5-HT2A agonists into front line anti-inflammatories.”

About Eleusis Ltd.

Founded in 2013, Eleusis is the first privately held, clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, guided by science and enabled by drug discovery, clinical development and care delivery design. The company’s comprehensive discovery, development and delivery capabilities enable it to target a broad spectrum of unmet needs within psychiatry, and beyond psychiatry. For more information, visit


Eleusis Inquiries:

Alex Speiser


Dan Gagnier / Jeffrey Mathews
Tel: 646-569-5897

Eleusis is a life science company based in London and New York, dedicated to transforming psychedelics into medicines

General & Media Inqueries

Careers Opportunities


New York